An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin.

CAS：387867-13-2
中文别名：4-[6-甲氧基-7-(3-哌啶-1-基丙氧基)喹唑啉-4-基]-N-(4-异丙基氧苯基)哌嗪-1-甲酰胺;MLN518;
英文别名：Tandutinib;MLN 518;Unii-E1io3icj9a;Tandutinib for research;
分子式：C31H42N6O4
分子量：562.703
精确质量：562.327
Psa：92.29
Logp：5.0483

MDL号：MFCD09954147

密度：1.213 g/cm3
沸点：769.5ºC at 760 mmHg
熔点：177-178°C
闪点：419.2ºC
折射率：1.61

RTECS号：AF8575000
安全说明：S23; S37; S45; S61
危险类别码：R25; R34; R50; R40; R36/37/38
WGK Germany：2
海关编码：29154000
危险品运输编码：UN 1751 6.1/PG 2
危险类别：6.1
包装等级：II
危险品标志：T; N; Xi; F

用途
抗癌原料药，新型免疫调节药,主要用于治疗多发性骨髓瘤和骨髓增生异常综合征。